Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 35 |
| List of Tables | 31 | 5 |
| List of Figures | 36 | 1 |
| Introduction | 37 | 1 |
| Global Markets Direct Report Coverage | 37 | 1 |
| Psoriasis Overview | 38 | 1 |
| Therapeutics Development | 39 | 2 |
| Pipeline Products for Psoriasis Overview | 39 | 1 |
| Pipeline Products for Psoriasis Comparative Analysis | 40 | 1 |
| Psoriasis Therapeutics under Development by Companies | 41 | 13 |
| Psoriasis Therapeutics under Investigation by Universities/Institutes | 54 | 1 |
| Psoriasis Pipeline Products Glance | 55 | 4 |
| Late Stage Products | 55 | 1 |
| Clinical Stage Products | 56 | 1 |
| Early Stage Products | 57 | 1 |
| Unknown Stage Products | 58 | 1 |
| Psoriasis Products under Development by Companies | 59 | 17 |
| Psoriasis Products under Investigation by Universities/Institutes | 76 | 1 |
| Psoriasis Companies Involved in Therapeutics Development | 77 | 145 |
| AbbVie Inc | 77 | 1 |
| Abeome Corporation | 78 | 1 |
| AbGenomics International, Inc. | 79 | 1 |
| Addex Therapeutics Ltd | 80 | 1 |
| Advinus Therapeutics Ltd | 81 | 1 |
| Affibody AB | 82 | 1 |
| Albireo AB | 83 | 1 |
| Almirall, S.A. | 84 | 1 |
| Alteogen Inc. | 85 | 1 |
| Amgen Inc. | 86 | 1 |
| Anacor Pharmaceuticals, Inc. | 87 | 1 |
| AnaptysBio, Inc. | 88 | 1 |
| ApoPharma Inc. | 89 | 1 |
| Arena Pharmaceuticals, Inc. | 90 | 1 |
| Argos Therapeutics, Inc. | 91 | 1 |
| Arrien Pharmaceuticals, LLC | 92 | 1 |
| AstraZeneca Plc | 93 | 1 |
| Athenex, Inc. | 94 | 1 |
| Aurigene Discovery Technologies Limited | 95 | 1 |
| Aurinia Pharmaceuticals Inc | 96 | 1 |
| Avexxin AS | 97 | 1 |
| Betta Pharmaceuticals Co. Ltd. | 98 | 1 |
| BioApex, s.r.o. | 99 | 1 |
| BIOCAD | 100 | 1 |
| Biocon Limited | 101 | 1 |
| BioLingus AG | 102 | 1 |
| BioMAS Ltd. | 103 | 1 |
| Biomics Biotechnologies Co., Ltd. | 104 | 1 |
| Bionomics Limited | 105 | 1 |
| Bionovis SA | 106 | 1 |
| Boehringer Ingelheim GmbH | 107 | 1 |
| Brickell Biotech, Inc. | 108 | 1 |
| Bristol-Myers Squibb Company | 109 | 1 |
| C4X Discovery Holdings PLC | 110 | 1 |
| CalciMedica, Inc. | 111 | 1 |
| Can-Fite BioPharma Ltd. | 112 | 1 |
| Celgene Corporation | 113 | 1 |
| Cell Medica Limited | 114 | 1 |
| Cellceutix Corporation | 115 | 1 |
| ChemoCentryx, Inc. | 116 | 1 |
| Chipscreen Biosciences Ltd | 117 | 1 |
| ChironWells GmbH | 118 | 1 |
| Clonz Biotech Private Limited | 119 | 1 |
| Coherus BioSciences, Inc. | 120 | 1 |
| Compugen Ltd. | 121 | 1 |
| Convoy Therapeutics, Inc. | 122 | 1 |
| Creabilis SA | 123 | 1 |
| Crescendo Biologics Limited | 124 | 1 |
| Curapel Limited | 125 | 1 |
| Cutanea Life Sciences, Inc. | 126 | 1 |
| Dermala Inc | 127 | 1 |
| Domainex Limited | 128 | 1 |
| Dr. August Wolff GmbH &Co. KG Arzneimittle | 129 | 1 |
| EA Pharma Co Ltd | 130 | 1 |
| Eli Lilly and Company | 131 | 1 |
| Epirus Biopharmaceuticals, Inc. | 132 | 1 |
| Exicure, Inc. | 133 | 1 |
| Foamix Pharmaceuticals Ltd. | 134 | 1 |
| Forward Pharma A/S | 135 | 1 |
| Gem Pharmaceuticals, LLC | 136 | 1 |
| Genentech, Inc. | 137 | 1 |
| Genor BioPharma Co., Ltd. | 138 | 1 |
| GlaxoSmithKline Plc | 139 | 1 |
| GlycoMar Limited | 140 | 1 |
| Grupo Ferrer Internacional, S.A. | 141 | 1 |
| HitGen LTD | 142 | 1 |
| Huabo Biopharm Co., Ltd. | 143 | 1 |
| Hydra Biosciences, Inc. | 144 | 1 |
| iCo Therapeutics Inc. | 145 | 1 |
| Idera Pharmaceuticals, Inc. | 146 | 1 |
| Immune Pharmaceuticals Inc. | 147 | 1 |
| Immune Response BioPharma, Inc. | 148 | 1 |
| Immungenetics AG | 149 | 1 |
| Innovent Biologics, Inc. | 150 | 1 |
| Jenrin Discovery, Inc. | 151 | 1 |
| Johnson &Johnson | 152 | 1 |
| Kadmon Corporation, LLC | 153 | 1 |
| KaloBios Pharmaceuticals, Inc. | 154 | 1 |
| KPI Therapeutics, Inc. | 155 | 1 |
| Lead Pharma Holding B.V. | 156 | 1 |
| Lee's Pharmaceutical Holdings Limited | 157 | 1 |
| LEO Pharma A/S | 158 | 1 |
| Lipidor AB | 159 | 1 |
| Lupin Limited | 160 | 1 |
| Lycera Corp. | 161 | 1 |
| mAbxience S.A. | 162 | 1 |
| Maruho Co., Ltd. | 163 | 1 |
| Medestea Research &Production S.p.A. | 164 | 1 |
| MediGene AG | 165 | 1 |
| Merck KGaA | 166 | 1 |
| MetrioPharm AG | 167 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 168 | 1 |
| Momenta Pharmaceuticals, Inc. | 169 | 1 |
| Mycenax Biotech Inc. | 170 | 1 |
| NeuClone Pty Ltd | 171 | 1 |
| Nimbus Therapeutics, LLC | 172 | 1 |
| NovaLead Pharma Pvt. Ltd. | 173 | 1 |
| Novan, Inc. | 174 | 1 |
| Novartis AG | 175 | 1 |
| Nuevolution AB | 176 | 1 |
| Numedii, Inc. | 177 | 1 |
| Oncobiologics, Inc. | 178 | 1 |
| OSE Immunotherapeutics | 179 | 1 |
| Panacea Biotec Limited | 180 | 1 |
| Pfizer Inc. | 181 | 1 |
| Pharis Biotec GmbH | 182 | 1 |
| Pharmedartis GmbH | 183 | 1 |
| Phenex Pharmaceuticals AG | 184 | 1 |
| Pieris Pharmaceuticals Inc | 185 | 1 |
| PinCell srl | 186 | 1 |
| Promius Pharma, LLC | 187 | 1 |
| Protalix BioTherapeutics, Inc. | 188 | 1 |
| Prothena Corporation Plc | 189 | 1 |
| Provectus Biopharmaceuticals, Inc. | 190 | 1 |
| RedHill Biopharma Ltd. | 191 | 1 |
| Rigel Pharmaceuticals, Inc. | 192 | 1 |
| Sandoz International GmbH | 193 | 1 |
| Sareum Holdings Plc | 194 | 1 |
| Selvita S.A. | 195 | 1 |
| Shanghai Celgen Bio-Pharmaceutical Co., Ltd. | 196 | 1 |
| Shulov Innovative Science Ltd. | 197 | 1 |
| Sigmoid Pharma Limited | 198 | 1 |
| Soligenix, Inc. | 199 | 1 |
| Spherium Biomed S.L. | 200 | 1 |
| Stemline Therapeutics, Inc. | 201 | 1 |
| sterna biologicals Gmbh &Co KG | 202 | 1 |
| Sucampo Pharmaceuticals, Inc. | 203 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 204 | 1 |
| SWITCH Biotech LLC | 205 | 1 |
| Syntrix Biosystems, Inc. | 206 | 1 |
| Takeda Pharmaceutical Company Limited | 207 | 1 |
| Tasly Pharmaceutical Group Co., Ltd. | 208 | 1 |
| Telormedix SA | 209 | 1 |
| Teva Pharmaceutical Industries Ltd. | 210 | 1 |
| TheraMAB LLC | 211 | 1 |
| Therapeutic Proteins International, LLC | 212 | 1 |
| Therapix Biosciences Ltd. | 213 | 1 |
| UCB S.A. | 214 | 1 |
| Valeant Pharmaceuticals International, Inc. | 215 | 1 |
| Vitae Pharmaceuticals, Inc. | 216 | 1 |
| Wellstat Therapeutics Corporation | 217 | 1 |
| XBiotech Inc | 218 | 1 |
| XenoPort, Inc. | 219 | 1 |
| Yuhan Corporation | 220 | 1 |
| Ziarco Pharma Ltd | 221 | 1 |
| Psoriasis Therapeutics Assessment | 222 | 27 |
| Assessment by Monotherapy Products | 222 | 1 |
| Assessment by Combination Products | 223 | 1 |
| Assessment by Target | 224 | 10 |
| Assessment by Mechanism of Action | 234 | 11 |
| Assessment by Route of Administration | 245 | 2 |
| Assessment by Molecule Type | 247 | 2 |
| Drug Profiles | 249 | 405 |
| (betamethasone dipropionate + calcipotriene) Drug Profile | 249 | 1 |
| (betamethasone dipropionate + calcipotriene) Drug Profile | 250 | 1 |
| (clarithromycin + clofazimine + rifabutin) Drug Profile | 251 | 8 |
| (halobetasol propionate + tazarotene) Drug Profile | 259 | 1 |
| A-3914 Drug Profile | 260 | 1 |
| A-5425 Drug Profile | 261 | 1 |
| AbGn-168H Drug Profile | 262 | 2 |
| ABS-11 Drug Profile | 264 | 1 |
| ABY-035 Drug Profile | 265 | 1 |
| adalimumab biosimilar Drug Profile | 266 | 2 |
| adalimumab biosimilar Drug Profile | 268 | 2 |
| adalimumab biosimilar Drug Profile | 270 | 2 |
| adalimumab biosimilar Drug Profile | 272 | 1 |
| adalimumab biosimilar Drug Profile | 273 | 1 |
| adalimumab biosimilar Drug Profile | 274 | 1 |
| adalimumab biosimilar Drug Profile | 275 | 1 |
| adalimumab biosimilar Drug Profile | 276 | 1 |
| adalimumab biosimilar Drug Profile | 277 | 3 |
| adalimumab biosimilar Drug Profile | 280 | 1 |
| adalimumab biosimilar Drug Profile | 281 | 1 |
| adalimumab biosimilar Drug Profile | 282 | 2 |
| adalimumab biosimilar Drug Profile | 284 | 2 |
| adalimumab biosimilar Drug Profile | 286 | 1 |
| adalimumab biosimilar Drug Profile | 287 | 1 |
| adalimumab biosimilar Drug Profile | 288 | 1 |
| adalimumab biosimilar Drug Profile | 289 | 1 |
| adalimumab biosimilar Drug Profile | 290 | 1 |
| adalimumab biosimilar Drug Profile | 291 | 1 |
| AGS-010 Drug Profile | 292 | 2 |
| AI-001 Drug Profile | 294 | 1 |
| AK-12 Drug Profile | 295 | 1 |
| AKP-11 Drug Profile | 296 | 2 |
| aminopterin sodium Drug Profile | 298 | 2 |
| amiselimod hydrochloride Drug Profile | 300 | 2 |
| Anatabine Drug Profile | 302 | 3 |
| ANB-019 Drug Profile | 305 | 1 |
| Antisense Oligonucleotide to Inhibit PDE4B for Psoriasis Drug Profile | 306 | 1 |
| Antisense RNAi Oligonucleotide for Psoriasis Drug Profile | 307 | 1 |
| apremilast Drug Profile | 308 | 11 |
| APY-0201 Drug Profile | 319 | 1 |
| ARN-4079 Drug Profile | 320 | 1 |
| ARN-6039 Drug Profile | 321 | 1 |
| AST-005 Drug Profile | 322 | 1 |
| AVX-001 Drug Profile | 323 | 1 |
| BA-1521 Drug Profile | 324 | 1 |
| BBI-3000 Drug Profile | 325 | 1 |
| BBI-6000 Drug Profile | 326 | 2 |
| BCD-085 Drug Profile | 328 | 1 |
| bertilimumab Drug Profile | 329 | 4 |
| betamethasone valerate Drug Profile | 333 | 1 |
| bimekizumab Drug Profile | 334 | 1 |
| BMS-986165 Drug Profile | 335 | 1 |
| BMS-986202 Drug Profile | 336 | 2 |
| BNC-164 Drug Profile | 338 | 1 |
| brodalumab Drug Profile | 339 | 6 |
| BTX-1308 Drug Profile | 345 | 1 |
| C-82 Drug Profile | 346 | 1 |
| calcipotriene Drug Profile | 347 | 1 |
| calcipotriene Drug Profile | 348 | 1 |
| calcipotriene Drug Profile | 349 | 1 |
| CB-001 Drug Profile | 350 | 1 |
| CBP-307 Drug Profile | 351 | 1 |
| CBS-3595 Drug Profile | 352 | 1 |
| CCX-991 Drug Profile | 353 | 1 |
| certolizumab pegol Drug Profile | 354 | 11 |
| CGEN-15001 Drug Profile | 365 | 3 |
| CJM-112 Drug Profile | 368 | 1 |
| CLS-008 Drug Profile | 369 | 1 |
| CM-2489 Drug Profile | 370 | 1 |
| CS-944X Drug Profile | 371 | 1 |
| CT-101 Drug Profile | 372 | 1 |
| CT-103 Drug Profile | 373 | 1 |
| cyclosporine Drug Profile | 374 | 1 |
| cyclosporine Drug Profile | 375 | 1 |
| cyclosporine IR Drug Profile | 376 | 1 |
| dalazatide Drug Profile | 377 | 5 |
| DFD-06 Drug Profile | 382 | 1 |
| dimethyl fumarate Drug Profile | 383 | 2 |